MMS Holdings Expert Insights Blog
Experts at MMS share their insights on trending
topics in the pharmaceutical industry.
MMS SmartStart™ Tech-Enabled Solution Eases Document Content Creation Process
CANTON, Mich. (September 22, 2021) - MMS Holdings Inc. (MMS) - an award-winning, data-focused CRO – announced the release of SmartStart™ Tech-Enabled Templates to reduce time and effort in the document content creation process while increasing the quality...
Challenges of Rare Disease Drug Development Programs
Why is drug development and research in the context of rare disease frequently more difficult to address? In this blog, we will outline some of the challenges with rare disease programs. What is a rare disease? Simply put, a rare disease or condition is one that...
Tips for Successful Medical Device Development and Approval
For Sponsors planning to manufacture or distribute a medical device in the US, understanding regulatory requirements is of the utmost importance. Medical device development and approval are regulated by the FDA, under the jurisdiction of the Center for Devices and...
How to Train Users on the Clinical Trial Information System (CTIS) Ahead of New Regulations
On 31 July 2021, the European Commission published a notice in the Official Journal of the European Union announcing that the EU Portal and Database, a key component of the Clinical Trial Information System (CTIS), is fully functional. This announcement starts...
Leadership, Culture, and Success: A Conversation with Prasad M. Koppolu, COO of a Clinical Research Organization (CRO)
For its leadership and culture as a clinical research organization (CRO) in the pharmaceutical industry, MMS has received much recognition and praise recently. To uncover some of the reasons behind this success, we recently sat down with Prasad M. Koppolu, Chief...
Pro-Bono Ultra-rare Disease Regulatory Assistance Program Created By MMS for Patient Advocacy Groups
CANTON, Mich. (August 12, 2021) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today the launch of its pro-bono support program aimed at advancing research for ultra-rare diseases. Within this program, MMS will select from patient advocacy...
Data CRO Expands its Virtual Learning Portfolio
Data CRO Expands its Virtual Learning Portfolio with New Life Sciences Courses in Inspection Readiness and Clinical Programming CANTON, Mich. (July 28, 2021) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced that its learning arm, MMS Academy, has...
MMS Poised for an Innovative Future with Best Clinical Research Organization Award and Two Key Executive Appointments
CANTON, Mich. (July 21, 2021) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO - announced the growth of its leadership team with the appointment of Kelly J. Hill to Executive Vice President (EVP) of Global Business Operations and Strategy and Michelle...
How to Maximize FSP Partnerships – Scalability, Innovation, and Efficiencies
FSP partnership models, when developed to find the right level of oversight, scale, pricing, and governance to meet a Sponsor’s needs, offer a functional provider solution that can benefit an organization in a rapidly evolving pharmaceutical industry. For example, The...